ADMA Biologics returning Bivigam to market after 3-year absence

ADMA Biologics bought its contract manufacturer to make it happen, but the company has finally gotten permission to return its primary immune deficiency disease drug Bivigam to the market. The FDA approval comes seven years after the drug was first anointed and three years after it was pulled from the market.